Showing 1251-1260 of 3024 results for "".
- Data Regarding Tolebrutinib Treatment for Nonrelapsing Secondary Progressive MS Presented and Publishedhttps://practicalneurology.com/news/tolebrutinib-significantly-reduced-disability-progression-in-non-relapsing-secondary-progressive-multiple-sclerosis/2474048/Treatment with tolebrutinib (Sanofi, Bridgewater NJ), a Bruton’s tyrosine kinase (BTK) inhibitor, significantly delayed disability progression in people with non-relapsing secondary progressive multiple sclerosis (nrSPMS). The full set of results from the phase 3 HERCULES clinical trial (NCT04411
- Experimental BTK Inhibitor Suppressed Inflammatory Disease Activity in Those with Relapsing MShttps://practicalneurology.com/news/long-term-treatment-with-fenebrutinib-suppressed-inflammatory-disease-activity-in-relapsing-ms/2473796/Fenebrutinib (Roche, Basel, Switzerland), an investigational oral, reversible noncovalent Bruton tyrosine kinase (BTK) inhibitor, demonstrated significant efficacy in suppressing inflammatory disease activity in people with relapsing multiple sclerosis (RMS) according to the results of the open-l
- Subcutaneous Ocrevus Zunovo Approved as Treatment for Primary Progressive and Relapsing MShttps://practicalneurology.com/news/subcutaneous-ocrevus-zunovo-approved-as-treatment-for-primary-progressive-and-relapsing-ms/2470576/The Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab & hyaluronidase-ocsq; Genentech, South San Francisco, CA) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). Ocrevus Zunovo is a subcutaneous formulation of
- Head-to-Head Comparison of Kesimpta vs Ocrevus Treatment in Patients with MShttps://practicalneurology.com/news/head-to-head-comparison-of-kesimpta-vs-ocrevus-treatment-in-patients-with-ms/2470485/Real-world study results presented at the 2024 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) demonstrated similar persistence and adherence of Kesimpta (ofatumumab; Novartis, East Hanover, NJ) treatment compared with Ocrevus (ocrelizumab; Genentech, South San Francisco, CA
- ~25% of Patients with MS Treated with Ocrevus Report Wearing-Off Phenomenonhttps://practicalneurology.com/news/25-of-patients-with-ms-treated-with-ocrevus-report-wearing-off-phenomenon/2470480/Study results presented at the 2024 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) revealed that nearly 25% of people with multiple sclerosis (PwMS) being treated with Ocrevus (ocrelizumab; Genentech, South San Francisco, CA) experienced a wearing-off phenomenon (ie, a retu
- Unexpected Association Found Between Certain Beverages and MS Riskhttps://practicalneurology.com/news/unexpected-association-found-between-certain-beverages-and-ms-risk/2470155/A study from Iran published in the Journal of Health, Population and Nutrition found that drinki
- Serum Glial Fibrillary Acidic Protein as Biomarker for MS Progressionhttps://practicalneurology.com/news/serum-glial-fibrillary-acidic-protein-as-biomarker-for-ms-progression/2470110/Serum glial fibrillary acidic protein (sGFAP) concentrations are
- Dimethyl Fumarate Delays MS in Those With Radiologically Isolated Syndromehttps://practicalneurology.com/news/dimethyl-fumarate-delays-ms-in-those-with-radiologically-isolated-syndrome/2470096/Results from the ARISE study (NCT02739542), published in the Annals of Neurology, demonstrated that dimethyl fumarate (Tecfidera; Biogen, Cambridge, MA) delayed the development of multiple scleros
- Phase 3 Trial of New Drug To Treat Progressive MS Approved by FDAhttps://practicalneurology.com/news/phase-3-trial-of-new-drug-to-treat-progressive-ms-cleared-by-fda/2470089/The Food and Drug Administration (FDA) approved a phase 3 clinical trial (NCT05441488) for masitinib (AB Science; Paris, France) as a potential treatment for progressive forms of multiple sclerosi
- Ofatumumab Reduced Annualized Relapse Rate in MS in Phase 3 Clinical Trialshttps://practicalneurology.com/news/ofatumumab-reduced-annualized-relapse-rate-in-ms-in-phase-3-clinical-trials/2469346/As published in The New England Journal of Medicine (NEJM), the ASCLEPIOS 1 (NCT02792218) and 2 (